COMPANY SHOWCASE: VETTER PHARMA

INJECTION

To Issue 160

Citation: “Company Showcase: Vetter Pharma”. ONdrugDelivery, Issue 160 (May 2024), pp 90–91.

Vetter Pharma is a leading global CDMO for the aseptic production of injectables (Figure 1). Since its founding in 1950 in Ravensburg (Germany) as a family-owned pharmacy, Vetter has grown to over 6,300 skilled employees worldwide. The company operates commercial production sites in Ravensburg and Langenargen (Germany) and clinical production facilities in Rankweil (Austria) and Chicago (IL, US) to supply patients worldwide with potentially life-saving drugs, as well as branch offices for Asia Pacific in Singapore, Japan, South Korea and China.

Figure 1: Vetter offers versatile single-source manufacturing services.

The company has international expertise working with regulatory authorities including the US FDA, EMA, PMDA (Japan) and RP (Germany). Vetter offers services for pharma and biotech firms of all sizes and locations and holds numerous patents, including technologies for protection against tampering and counterfeiting. Vetter’s expertise ranges from lyophilisation (freeze-drying) to siliconisation and more. Vetter’s mission is to produce drugs that enhance patient safety, comfort and compliance by providing tailored solutions to meet their partners’ specific market needs. The company has been carbon neutral at all its corporate sites since 2021.

Figure 2: Vetter manufactures sterile injectables through a highly complex, controlled and precise process.

A FOCUS ON ENSURING CUSTOMERS’ SUCCESS

As a globally operating CDMO partner, Vetter produces aseptically prefilled syringes, cartridges, vials and dual-chamber systems (Figure 2). It is an independent company rooted in over 70 years of history. Vetter does not manufacture its own drugs, instead focusing on providing highly skilled support and state-of-the art manufacturing resources to pharma partners. Vetter supports its customers from the initial phases of clinical drug product development and filling through to commercial manufacturing, device assembly, packaging and lifecycle management (Figure 3). More than 80% of the company’s active projects are biologics.

Figure 3: Vetter supports customers in identifying the right packaging strategies for their unique drug compounds.

“Vetter supports its customers from the initial phases of clinical drug product development and filling through to commercial manufacturing, device assembly, packaging and lifecycle management.”

A RELIABLE, RESPONSIVE AND PROGRESSIVE PARTNER

Vetter’s portfolio of services includes dedicated resources for clinical development; commercial manufacturing, assembly and packaging; and more. Vetter offers the following services:

• Drug Product Development: Support in navigating key decisions early in a product’s evolution with scalability, quality and efficiency in mind.
• Aseptic Filling and Visual Inspection: Comprehensive expertise in manufacturing injectable drug products and related visual inspection systems.
• Device Assembly and Packaging: Strategic, technical and packaging support for patient-friendly combination products.
• Analytical Services: Robust, customisable testing methods for drug products, including evaluation and quality verification.
• Regulatory Support: Support in achieving milestones related to regulatory compliance during clinical development, market authorisation and beyond.
• Logistic Services: Cutting-edge solutions that maximise efficiency, transparency and precision of vital supply chains.

What's this?